Overview
ACAD market data
Price History
ACAD price chart · 1M
- O
- 28.93
- H
- 28.96
- L
- 27.63
- C
- 27.85
- Vol
- 180,312.00
- Source
- US equities market feed
- Observed
- Sep 3, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $28.93
- Previous Close
- $28.92
- Day High
- $28.96
- Day Low
- $27.63
- 52 Week High
- $30.94
- 52 Week Low
- $20.31
- 7 Day Return
- -6.31%
- 30 Day Return
- +2.47%
- 90 Day Return
- +29.17%
- 1 Year Return
- +23.39%
- Daily Notional Volume
- $5M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 12.85 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $2.30 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.86 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 33.4% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $19.69 – $30.96 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $4.9B · P/B 3.68 · P/S 4.29.
Company News
10 captured
Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $38Benzinga · Aug 25, 2026, 5:05 PM
Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $28Benzinga · Aug 25, 2026, 3:28 PM
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $40Benzinga · Aug 25, 2026, 3:28 PM
European Commission Approves Acadia’s DAYBU For Rett Syndrome Patients Aged Five And Older Following Successful Phase 3 LAVENDER StudyBenzinga · Aug 24, 2026, 1:28 PM
UBS Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $49Benzinga · Aug 17, 2026, 2:28 PM
Needham Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $41Benzinga · Aug 12, 2026, 10:05 AM
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $39Benzinga · Aug 10, 2026, 3:11 PM
Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Raises Price Target to $25Benzinga · Aug 5, 2026, 5:14 PM
ACADIA Pharmaceuticals shares are trading higher after Citizens and RBC Capital raised their respective price targets on the stock.Benzinga · Aug 5, 2026, 4:49 PM
RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $37Benzinga · Aug 5, 2026, 3:21 PM